butabarbital will decrease the level or result of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified. These agents should only be combined if choice therapy selections are insufficient. If mixed, limit the dosages and duration of each drug.